Navigation Links
VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
Date:10/27/2009

xchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the backlog and new customer awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

    CONTACT:
              Molly Henderson
              Chief Business and Financial Officer
              500 Linden Oaks
              Rochester, New York 14625
              (585)249.6231

SOURCE VirtualScopics, Inc.


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. VirtualScopics to Present at the 8th Annual Bio Investor Forum
2. VirtualScopics Project Balance Exceeds a Record $35 Million
3. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
6. Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings
7. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
8. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
9. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
10. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
11. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential ... ("Advaxis" or the "Company") (NASDAQ: ADXS ), ... to shareholders. On January 21, 2015, an ... Advaxis had misrepresented the clinical data for its ADXS-HPV ...
(Date:1/23/2015)... Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of ... compound, LB‑100, is being conducted, has been expanded from 1 ... M.D., the founder and President of Lixte, said that, "the ... site. Accrual of patients, however, was slower than projected. The ...
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who ... are thrilled to have it lead the wedding dress industry ... of prom dresses for the global market. , “The CEO ... and he focuses on continuing the goal of operational excellence ...
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... NEW YORK, Sept. 28 Small Bone Innovations,Inc. ... education,for the small bone and joint orthopedic market ... Radial Head Implant System. To further,augment its Elbow ... System for internal fixation of proximal radius,fractures. ...
... Admission for All Children on October 6th, CAMBRIDGE, ... division of Shire plc, the global specialty,biopharmaceutical company, invites ... Museum on Saturday, October 6th for,"Shire Day" when all ... be granted,free admission. As part of the day, all ...
... directed health plan (CDHP) offerings are more engaged ... and save for healthcare,expenses than those in traditional ... by the Blue Cross and Blue Shield,Association (BCBSA). ... found that consumers,eligible for health savings accounts (HSAs) ...
... of a particular lung tumor can help clinicians make ... first. , A new study led by researchers from ... Institute for Genome Sciences & Policy (IGSP) found distinct ... used chemotherapy drugs. , We were able to ...
... Transcept,Pharmaceuticals, Inc., a specialty pharmaceutical company deriving,significant ... announced,that Glenn A. Oclassen, President and Chief Executive ... Investor Forum at the Palace Hotel in San,Francisco ... Pacific Time. About Transcept Pharmaceuticals Transcept ...
... - Renowned physicians provide viewers with important information on the use, ... ... strokes -, SILVER SPRING, Md., ... its use in the primary and,secondary prevention of cardiovascular and cerebral-vascular events.,Premiering ...
Cached Medicine News:Health News:SBi Launches rHead(TM) Lateral Radial Head Implant and rHead(TM) Plating Systems to Expand its Elbow Management System 2Health News:SBi Launches rHead(TM) Lateral Radial Head Implant and rHead(TM) Plating Systems to Expand its Elbow Management System 3Health News:SBi Launches rHead(TM) Lateral Radial Head Implant and rHead(TM) Plating Systems to Expand its Elbow Management System 4Health News:Families Invited to Celebrate 'Shire Day' at Boston Children's Museum 2Health News:Blue Cross And Blue Shield Association Survey Shows Consumer Driven Health Plan Enrollees Are Taking More Control of Their Healthcare 2Health News:Blue Cross And Blue Shield Association Survey Shows Consumer Driven Health Plan Enrollees Are Taking More Control of Their Healthcare 3Health News:Genomic profiling of lung tumors helps doctors choose most effective treatment 2Health News:Genomic profiling of lung tumors helps doctors choose most effective treatment 3Health News:Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits 2Health News:Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits 3Health News:Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits 4
... Colorimetric Assay ... (UH) and Low ... (LMWH).Chromogenic substrate CBS ... freeze-dried; purified bovine ...
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor V Assay by STA© Analyzers. Freeze-dried human plasma, artificially depleted of factor V....
Substrate Plasma for Factor X Assay by STA© Analyzers. Freeze-dried human plasma from which factor X has been removed by selective immuno-adsorption....
Medicine Products: